When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations (Q38211695)

31 August 2017

title

When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations (English)

1 reference

31 August 2017

0 references

Cécile Gaujoux-Viala

0 references

Laure Gossec

series ordinal

object named as

Laure Gossec

1 reference

31 August 2017

Cécile Gaujoux-Viala

1 reference

31 August 2017

language of work or name

English

0 references

publication date

14 May 2014

1 reference

Annals of the New York Academy of Sciences

31 August 2017

published in

1 reference

31 August 2017

volume

1318

1 reference

31 August 2017

page(s)

32-40

1 reference

Optimized glucocorticoid therapy: teaching old drugs new tricks

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

The clinical effect of glucocorticoids in patients with rheumatoid arthritis may be masked by decreased use of additional therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Randomized withdrawal of long-term prednisolone treatment in rheumatoid arthritis: effects on inflammation and bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Therapies for active rheumatoid arthritis after methotrexate failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

The timing of prednisolone dosage and its effect on morning stiffness in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

The timing of glucocorticoid administration in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

Effect of novel therapeutic glucocorticoids on circadian rhythms of hormones and cytokines in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12452

21 January 2018

Identifiers

DOI

10.1111/NYAS.12452

1 reference

31 August 2017

1 reference